Vita

Lechner, B., Lechner, K., Freibothe, I. et al. “Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.” Cardiovasc. Diabetol. – Endocrinol. Rep. 12, 50 (2026). https://doi.org/10.1186/s40842-026-00318-z

Lechner K, Zhang S, Krüger N, Krefting J, Wolf K, Dallavalle M, Dreischulte T, Offenborn F, Starnecker F, von Scheidt M, Chen K, Peters A, Breitner S, Schneider A, Schunkert H. “Upward Air Temperature Shifts and Acute Cardiovascular Events in Individuals with Atherosclerotic Cardiovascular Disease: A Time-Stratified Case-Crossover Study.” Lancet Reg Health Eur. 2026 Jun 4;67:101730.

Katharina Lechner, Benjamin Lechner, Oliver Weingärtner. “Plaque regression: Risk status or ApoB exposure?” Atherosclerosis 415, 120719.

Maximilian Jonathan Herzog et al. “Arterial stiffness and vascular aging: mechanisms, prevention, and therapy”. Signal Transduction and Targeted Therapy 10.1, 282.

Wenli Ni et al. “Low and high air temperature and cardiovascular risk”. Atherosclerosis, 119238.

Katharina Lechner et al. “Hitze und kardiovaskuläres Risiko”. Die Kardiologie 18.2, 120–126.

Lechner K. et al. “Cardiometabolic and immune response to exercise training in patients with metabolic syndrome”. Frontiers in Cardiovascular Medicine 11, 1329633.

M. Bock et al. “De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF Patients”. J Clin Med 12.15.

A. Dutsch et al. “Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19”. J Clin Med 12.19.

Lechner K. et al. “Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF”. Clinical Research in Cardiology.

Lechner K. et al. “Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men”. Naunyn-Schmiedeberg’s Archives of Pharmacology.

Richard D. Feinman et al. “Re-evaluating low-carbohydrate diets and mortality”. The Lancet Public Health 7.7, e581.

Lechner K. and Ronald M. Krauss. “Obesity and cardiovascular disease: beyond body weight and energy balance”. European Journal of Preventive Cardiology 29.17, 2216–2217.

Lechner K. et al. “Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF”. Biomedicines 10.9, 2296.

Lechner K. et al. “Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients”. Clinical Research in Cardiology 111.3, 308–321.

N. Worm et al. “Gesättigte Fettsäuren und kardiovaskuläres Risiko”. Herz 47.4, 354–365.

Etienne Cavalier et al. “Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression”. Frontiers in Molecular Biosciences 8.

Lechner K. et al. “Your athlete-patient has a high coronary artery calcification score—‘Heart of Stone’. What should you advise? Is exercise safe?” British Journal of Sports Medicine 55.18, 1001.

Lechner K. et al. “Waist-to-height ratio and metabolic phenotype compared to the Matsuda index for the prediction of insulin resistance”. Scientific Reports 11.1, 8224.

Shaminie J. Athinarayanan et al. “Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes”. Cardiovascular Diabetology 19.1, 208.

Pia von Korn et al. “The Effect of Exercise Intensity and Volume on Metabolic Phenotype in Patients with Metabolic Syndrome”. Metabolic Syndrome and Related Disorders 19.2, 107–114.

Lechner K. et al. “Exercise recommendations in athletes with coronary artery calcification”. European Journal of Preventive Cardiology 27.8, 882–884.

Lechner K., Thorsten Kessler, Heribert Schunkert. “Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?” Current Cardiology Reports 22.11, 146.

Lechner K. et al. “The ‘heart’ of preventive cardiology: Lifestyle medicine for the treatment of cardiometabolic diseases”. European Journal of Preventive Cardiology 27.19, 2069–2070.

Lechner K. et al. “High-Risk Atherosclerosis and Metabolic Phenotype”. Metabolic Syndrome and Related Disorders 18.4, 176–185.

Lechner K. et al. “Lifestyle factors and high-risk atherosclerosis”. European Journal of Preventive Cardiology 27.4, 394–406.

Lechner K. and Clemens von Schacky. “How to prevent cardiovascular events from recurring”. European Journal of Preventive Cardiology 29.10, e295–e297.

Lechner K. and Heribert Schunkert. “Recommendations on sodium intake for cardiovascular health”. European Heart Journal 41.35, 3374–3375.

U. Gonder et al. “[Dementia and Metabolic-Vascular Risk Factors: Strategies for Prevention]”. Dtsch Med Wochenschr 144.17, 1212–1217.

J. M. Hennings et al. “Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men”. JCI Insight 4.1.

Lechner K. and M. Halle. “Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?” JAMA Cardiology 4.9, 950–951.

C. Bamberger et al. “A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects”. Nutrients 10.2.

C. Bamberger et al. “A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects”. Nutrients 9.10.

Lechner K. et al. “[Dietary Recommendations in Metabolic Vascular Syndrome]”. Dtsch Med Wochenschr 142.21, 1613–1626.

Lechner K. and K. G. Parhofer. “[Dietary advice for preventing and treating T2DM: A shift of paradigm]”. MMW Fortschr Med 158.7, 41–44.

Lechner K. et al. “Hydrothermally modified slow release corn starch: a potential new therapeutic option for treating hypoglycemia in autoimmune hypoglycemia”. European Journal of Clinical Nutrition 69.12, 1369–1370.